Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland’s 20 largest listed companies, market operator SIX said on Tuesday.
Information about any other changes to SMI and Switzerland’s other indexes will be released later, the bourse said.
Novartis last year announced the spin off of Alcon to the Basel drugmaker’s shareholders in the first half of this year.
Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.
By John Revill
Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is over—just […]
Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was […]
Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting. […]